secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2026-06-11T13:20:32+00:00
Accession:  0001171843-26-004053
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech announces $3.5M PIPE led by CEO; funds vitiligo program
---------------------------------------------------------------------

- Gross proceeds ~$3.5M from sale of 729,241 common shares to healthcare-focused investors and CEO.
- Investors pay $4.69/share; CEO pays $5.21/share; closing expected June 15, 2026.
- Net proceeds to fund advancement of vitiligo program and drug candidate paridiprubart, plus working capital.
- Company entered Registration Rights Agreement to file resale registration statement within 45 days of closing.
- Securities offered under Section 4(a)(2) and Regulation D; no underwriter or placement agent used.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326004053/0001171843-26-004053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326004053/f8k_061026.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer